1 Guidance

1 Guidance

1.1 Trabectedin is recommended as a treatment option for people with advanced soft tissue sarcoma if:

  • treatment with anthracyclines and ifosfamide has failed or

  • they are intolerant of or have contraindications for treatment with anthracyclines and ifosfamide.

    Trabectedin is only recommended if the company provides it according to the commercial arrangement.

1.2 This recommendation is not intended to affect treatment with trabectedin that was started in the NHS before this guidance was published. People having treatment outside this recommendation may continue without change to the funding arrangements in place for them before this guidance was published, until they and their NHS clinician consider it appropriate to stop.

  • National Institute for Health and Care Excellence (NICE)